| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
https://www.bloomberg.com/news/articles/2025-10-28/us-fires-top-health-official-who-opposed-widely-used-covid-shots?srnd=homepa...
Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on Novavax (NASDAQ:NVAX) with a Overweight rating and announc...
HC Wainwright & Co. analyst Sean Lee maintains Novavax (NASDAQ:NVAX) with a Buy and raises the price target from $10 to ...
Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least...
- SEC 13D/ Amended Filing
Reports $220 Million in Aircraft SalesNovavax, Inc. (NASDAQ:NVAX) has completed the transfer of the marketing authorization for...
GAITHERSBURG, Md., Sept. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced progress on its collaboration an...